Therefore, in peri- and post-menopausal patients, rapid or substantial weight loss while on semaglutide may plausibly unmask or intensify GSM symptoms via endocrine and tissue-level changesalthough the specific contribution of semaglutide vs weight loss per se is not established
As with the injectable Wegovy, this will require a NICE appraisal before NHS prescribing can begin, and initial access is likely to be restricted to specialist weight management services
Clinical Milestone: Tafenoquine cleared the Babesia parasite in the first patient of its ongoing trial, prompting a Breakthrough Therapy Designation request to the FDA
Kanda E, Ai M, Yoshida M, Kuriyama R, Shiigai T
In addition, we amplified one garlic cDNA fragment using degenerate primers designed based on the conserved regions of known plant GGTs